Health and Me

Ishita Roy

Wegovy Pill: FDA Says The TV Ad By Novo Nordisk On Its Weight Loss Pills Are Misleading

<span>Wegovy pill</span> by <span>Novo Nordisk</span> is now under scrutiny after the US Food and Drug Administration (FDA) raised concerns over a television advertisement. FDA said that the commercial includes "false and misleading" claims about the obesity drug's benefits. 

In a letter (reported first by <em>Bloomberg</em>) dated February 5, the FDA said the advertisement misbrands the oral weight loss drug. FDA said that it made its distribution a potential violation of federal law. FDA has asked the Danish drugmaker to take immediate corrective action, which include:

<ul><li>Pulling the ad</li><li>Revising all advertisements that contain misleading statements</li></ul>

<h2><span rel="noindex">Wegovy</span> Pill: FDA Questions Claims of Superiority and Emotional Benefits</h2>

As per the letter, the FDA found that the ad misleadingly suggests the Wegovy pill offers superior benefits when compared to other approved GLP-1 weight loss drugs. The regulator flagged phrases such as “live lighter” and “a way forward,” saying they imply greater weight loss and added advantages without evidence to support those claims.

The FDA also took issue with what it describes as emotional and psychological messaging, saying that the ad appears to imply benefits beyond physical weight loss, including emotional relief, reduced psychological burden, hope, or direction in life. FDA notes that this claim positions the drug as a solution to broader life challenges rather than just a treatment to obesity. 

Furthermore, FDA said that the ad failed to adequately present risk information in both audio and text formats, which is mandatory requirement for television drug advertising. 

<h2>Wegovy Pill: Novo Nordisk Responds To FDA Notice</h2>

Novo Nordisk confirmed on Monday that it has received the FDA’s letter. The company clarified that while the advertisement has been running since the pill’s launch, it is not linked to its Super Bowl advertising.

“We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” said Liz Skrbkova, Novo Nordisk’s head of US media and stakeholder relations, in a statement.

Novo Nordisk is already under pressure to defend its position in the weight loss market, as it is facing a stiff competition from rival Eli Lilly. Furthermore, on Monday, Novo also filed a lawsuit against telehealth company <a href="https://www.healthandme.com/health-news/cheaper-copy-of-wegovy-pill-by-hims-hers-now-available-for-49-novo-nordisk-says-it-will-take-legal-actions-article-153568449" data-type="tilCustomLink">Hims &amp; Hers</a>, seeking to block the mass marketing of compounded versions of its Wegovy pill and injections.

Read: <a href="https://www.healthandme.com/health-wellness/wegovy-pills-now-available-at-your-pharmacies-heres-what-to-know-about-its-usage-article-153401682" data-type="tilCustomLink">Wegovy Pills Now Available At Your Pharmacies, Here's What To Know About Its Usage</a> 

<h2>Wegovy Pill: How Effective Is It?</h2>

After injection by Novo Nordisk, of the same name, Wegovy, which has been on the market since 2021, its popularity grew so much that it was in short supply until February 2025. The pill version has now come out, which many experts believe will expand its accessibility. As the monthly supply of pill is expected to be cheaper than the monthly supply of the weight loss injection.

A study published in the New England Journal of Medicine show that a 25 milligram Wegovy pill led to 13.6% reduction in weight on average over 64 weeks. When compared to placebo, the result was only 2.2% of weight loss. Novo Nordisk says that those who stayed on the treatment and reduced their calorie intake, it would lead to a loss of 16.6% of their weight.

<h2>Wegovy Pill: What Are The Side Effects?</h2>

Digestive problems such as nausea and vomiting remain the most common side effects of GLP-1 drugs. These issues were also reported in studies of the pill versions. Around 7 percent of participants taking the Wegovy pill stopped treatment because of side effects, compared with 6 percent in the placebo group. In orforglipron’s trial, up to 10 percent of patients discontinued treatment, compared with 3 percent on placebo.

One key difference lies in how the medications are used. The Wegovy pill must be taken on an empty stomach with a small amount of water. Patients are advised not to eat, drink, or take other medicines for at least 30 minutes afterward. Doctors say this requirement has limited the use of Rybelsus, the pill form of <span>semaglutide</span> approved for diabetes, compared with Ozempic.

Health Conditions A-Z

health

Wegovy Pill

wegovy

weight loss pills

glp1

wegovy fat loss pills

semaglutide

novo nordisk

semaglutide weight loss

health news

health news USA

Fact Check: Doctors Bust Common Myths Around Epilepsy and Explain Why Early Treatment Matters

After 50, Your Body Steals Magnesium From Bones, Says Neuroscientist

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Wegovy pill by Novo Nordisk is now under scrutiny after the US Food and Drug Administration (FDA) raised concerns over a television advertisement. FDA said that the commercial includes "false and misleading" claims about the obesity drug's benefits. In a letter (reported first by Bloomberg) dated February 5, the FDA said the advertisement misbrands the oral weight loss drug. FDA said that it made its distribution a potential violation of federal law. FDA has asked the Danish drugmaker to take immediate corrective action, which include:Pulling the adRevising all advertisements that contain misleading statementsWegovy Pill: FDA Questions Claims of Superiority and Emotional BenefitsAs per the letter, the FDA found that the ad misleadingly suggests the Wegovy pill offers superior benefits when compared to other approved GLP-1 weight loss drugs. The regulator flagged phrases such as “live lighter” and “a way forward,” saying they imply greater weight loss and added advantages without evidence to support those claims.The FDA also took issue with what it describes as emotional and psychological messaging, saying that the ad appears to imply benefits beyond physical weight loss, including emotional relief, reduced psychological burden, hope, or direction in life. FDA notes that this claim positions the drug as a solution to broader life challenges rather than just a treatment to obesity. Furthermore, FDA said that the ad failed to adequately present risk information in both audio and text formats, which is mandatory requirement for television drug advertising. Wegovy Pill: Novo Nordisk Responds To FDA NoticeNovo Nordisk confirmed on Monday that it has received the FDA’s letter. The company clarified that while the advertisement has been running since the pill’s launch, it is not linked to its Super Bowl advertising.“We take all regulatory feedback seriously and are in the process of responding to the FDA to address their concerns regarding the advertisement’s presentation,” said Liz Skrbkova, Novo Nordisk’s head of US media and stakeholder relations, in a statement.Novo Nordisk is already under pressure to defend its position in the weight loss market, as it is facing a stiff competition from rival Eli Lilly. Furthermore, on Monday, Novo also filed a lawsuit against telehealth company Hims & Hers, seeking to block the mass marketing of compounded versions of its Wegovy pill and injections.Read: Wegovy Pills Now Available At Your Pharmacies, Here's What To Know About Its Usage Wegovy Pill: How Effective Is It?After injection by Novo Nordisk, of the same name, Wegovy, which has been on the market since 2021, its popularity grew so much that it was in short supply until February 2025. The pill version has now come out, which many experts believe will expand its accessibility. As the monthly supply of pill is expected to be cheaper than the monthly supply of the weight loss injection.A study published in the New England Journal of Medicine show that a 25 milligram Wegovy pill led to 13.6% reduction in weight on average over 64 weeks. When compared to placebo, the result was only 2.2% of weight loss. Novo Nordisk says that those who stayed on the treatment and reduced their calorie intake, it would lead to a loss of 16.6% of their weight.Wegovy Pill: What Are The Side Effects?Digestive problems such as nausea and vomiting remain the most common side effects of GLP-1 drugs. These issues were also reported in studies of the pill versions. Around 7 percent of participants taking the Wegovy pill stopped treatment because of side effects, compared with 6 percent in the placebo group. In orforglipron’s trial, up to 10 percent of patients discontinued treatment, compared with 3 percent on placebo.One key difference lies in how the medications are used. The Wegovy pill must be taken on an empty stomach with a small amount of water. Patients are advised not to eat, drink, or take other medicines for at least 30 minutes afterward. Doctors say this requirement has limited the use of Rybelsus, the pill form of semaglutide approved for diabetes, compared with Ozempic.